First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS). Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803. HOUSTON, May 2, 2023 /PRNewswire/ — Cellenkos® Inc., a clinical stage biotechnology company focused on developing…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.